Low desire от menopause has multiple drivers — hormonal, GSM, mood, sleep. Treatment matches root cause.
Hypoactive sexual desire disorder (HSDD) в menopause is multifactorial. Estrogen loss, painful intercourse от GSM, low testosterone, sleep deprivation, и mood changes все contribute.
Common в peri + postmenopause. Often coexists с other symptoms. Effective treatment requires identifying the dominant driver.
All options below are real published treatments. Evidence-level reflects current clinical guidelines (NAMS / ACOG / Endocrine Society). Cost ranges are starting price estimates от $US public sources.
Monthly cost
$30-$120
Side effects
minimal
If painful intercourse is а driver, fixing dyspareunia often restores desire indirectly.
Providers offering this: midi health, alloy womens health
Monthly cost
$60-$200
Side effects
acne, hirsutism (mild), voice changes (rare at proper dose)
No FDA-approved testosterone formulation для women, но global menopause societies endorse off-label transdermal use в postmenopausal HSDD. Effect modest but real.
Contraindications: Hormone-sensitive cancer history, pregnancy
Providers offering this: alloy womens health, midi health
Monthly cost
$400-$900
Side effects
dizziness, somnolence, hypotension
Daily oral. FDA-approved только для premenopausal women с HSDD. Modest effect; requires abstaining от alcohol.
Monthly cost
$300-$1000 (per injection)
Side effects
nausea, flushing, transient hypertension
On-demand subcutaneous injection 45 min before activity. FDA-approved для premenopausal HSDD только. Limited adoption due к cost + nausea.
Endorsed by global societies for postmenopausal HSDD using transdermal preparations at physiologic doses (≤300 mcg/day). Long-term safety data still emerging — most studies к 2 years suggest safety profile с monitoring.
Last verified 2026-06-01. Treatment guidelines update — confirm с your clinician.